Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic Oncology and Neurology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ASH1L drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ASH1L SET Domain Recombinant Protein (High purity >95%, Endotoxin <1 EU/ug, Sequence Verified; includes catalytically inactive mutant controls) | View ASH1L Products |
| Gene Delivery | ASH1L Lentivirus/Lentiviral Particles (Full-length ORF for stable cell line construction; HEK293T packaged, high titer) | View ASH1L Products |
| Benchmark Ab | Anti-ASH1L (Research Grade / ChIP-Grade Antibody; recombinant positive control for western blot, IP, and ChIP) | View ASH1L Products |
| Validator | ASH1L siRNA Set (3 unique sequences for knockdown verification and specificity controls; optimized for PROTAC validation) | View ASH1L Products |
| Related Target A | Menin (Synergistic oncogenic pathway partner in MLL-rearranged leukemias) | View Menin Products |
| Related Target B | MLL1 (Core complex mediator for targeted degradation and combination therapies) | View MLL1 Products |
| Related Target C | EZH2 (Opposing PRC2 complex methyltransferase; combinatorial epigenetic strategy) | View EZH2 Products |
| Related Target D | BRD4 (Epigenetic reader protein; synthetic lethality with H3K36me defects) | View BRD4 Products |
| Related Target E | NSD2/WHSC1/MMSET (H3K36 methyltransferase; paralog selectivity assessment) | View NSD2 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily counter screening (NSD1/2/3, SETD2, EZH2) | Homolog panel proteins strictly verified by mass spectrometry and sequence alignment. |
| PROTAC ternary complex formation assays | High-purity SET domain proteins with Native E. coli or Sf9 expression to ensure proper folding; full-length constructs available. |
| Lack of Controls | Sequence-verified antibodies and benchmark tool compounds included; catalytic dead mutant (D1249A) and gatekeeper mutants provided. |
| False Positives in knockdown assays | Valid sequence-optimized siRNA included for specificity checks. |
| Cellular target engagement & occupancy | Lentivirus-based stable cell lines for H3K36me2 level monitoring via flow cytometry or IP; ChIP-grade antibodies for direct engagement. |
| Resistance mutation profiling | Custom mutant proteins (including dbSNP variants rs186255422, rs1293246328) available for counter-screening. |
Live ASH1L R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
- ➤ Latest Inhibitor Research
Global Clinical Landscape & Future Outlook
The race for ASH1L therapeutics is intensifying, representing a frontier in epigenetic drug discovery. ASH1L (ASH1 Like Histone Lysine Methyltransferase) is a histone H3K36 methyltransferase that regulates transcriptional elongation and DNA repair pathways. It contains multiple functional domains: AWS (associated with SET), SET (catalytic), and Post-SET, which together mediate methylation activity. The target is highly sought after in MLL-rearranged leukemias, acute myeloid leukemia (AML), solid tumors (e.g., H3.3K36M gliomas), and neurodevelopmental disorders. Currently in preclinical validation, the field is shifting from traditional small molecule inhibitors toward targeted protein degradation (PROTAC) modalities to overcome selectivity challenges within the crowded KMT family. First-generation tool compounds (e.g., AS-99) pave the way for clinical candidates, and next-wave R&D targets dual-mechanism degraders and synergistic combinations with Menin/MLL inhibitors to overcome resistance. The large multi-domain nature of ASH1L (~3000 aa) necessitates modular protein reagents for assay development.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academic/Biotech Consortiums | Acute Leukemias, AML, Myeloid Malignancies, Solid Tumors | Selectivity Assay (Need high-purity Homologs vs WT SET domains) |
| PROTAC Degrader | Early-stage Biopharmas | MLL-r Leukemias, Solid Tumors (H3.3K36M) | Ternary Complex Validation (Need strictly purified full-length or SET domain proteins) |
| Combination Therapy | Oncology focused Biotechs | Refractory Hematological Malignancies | Pathway Analysis (Need related target proteins like Menin/MLL1, EZH2, BRD4) |
| Allosteric Modulator | Discovery Stage | Neurodevelopmental Disorders | Conformational Binding Assay (Need bromodomain/PHD finger constructs) |
Functional Domains & Key Mutations
ASH1L (UniProt Q9NR48) comprises three key functional domains: AWS (N-terminal), SET (catalytic methyltransferase core), and Post-SET (C-terminal regulatory). The SET domain is the primary target for small molecule inhibitors and PROTACs. Clinically relevant mutations include dbSNP rs186255422 (uncertain significance) and two variants linked to MRD52 (mental retardation, autosomal dominant 52): rs1293246328 (uncertain significance) and an additional uncharacterized variant. TarMart offers recombinant protein constructs covering these domains and can generate custom mutant proteins for selectivity and resistance profiling.